Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress [Yahoo! Finance]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: Yahoo! Finance
On March 13, Bank of America Securities maintained a Buy rating on Mineralys Therapeutics Inc. (NASDAQ:MLYS). The firm increased its price target to $51 from $46, citing recent updates on the clinical development progress of its lead drug, lorundrostat, following the fourth quarter earnings report. adriaticfoto/Shutterstock.com It added that the therapy's peak sales opportunity in treating uncontrolled hypertension remains underappreciated, supporting a more constructive view on the company's long-term potential. On March 13, Mineralys Therapeutics Inc. (NASDAQ:MLYS) Chief Executive Officer Jon Congleton stated that 2025 was a transformative year for Mineralys. The year was marked by significant clinical advancements and important regulatory achievements, as it was able to finish many of the clinical trials. Congleton highlighted that the results indicate lorundrostat to be of use to people whose hypertension is poorly controlled. He also stated that the company submitted its
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal OfficerGlobeNewswire
- Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? [Yahoo! Finance]Yahoo! Finance
- R1 starts up with $78M, aiming for a better kidney drug [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
MLYS
Earnings
- 3/12/26 - Beat
MLYS
Sec Filings
- 4/17/26 - Form 144
- 4/15/26 - Form 4
- 4/15/26 - Form 4
- MLYS's page on the SEC website